It is currently unknown whether HIF2α inhibitors (e.g., belzutifan) are effective for SDHB mutant PCPG, but it is plausible that co-operative EPAS1 mutations could make these tumours more sensitive69. The gene discussed is SDHB; the disease is neoplasm.